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Abstract  9 
Many oncology studies incorporate a blinded, independent central radiological review (BICR) to make an 10 
assessment of the integrity of the primary endpoint, progression free survival (PFS).   Recently it has 11 
been suggested that, in order to assess the potential for bias amongst investigators, a BICR amongst 12 
only a sample of patients could be performed; if evidence of bias is detected, according to a pre-defined 13 
threshold, the BICR is then assessed in all patients, otherwise it is concluded the sample was sufficient to 14 
rule-out meaningful levels of bias.  In this paper, we present an approach that adapts a method 15 
originally created for defining futility bounds in group sequential designs.  The hazard ratio ratio (HRR), 16 
the ratio of the hazard ratio (HR) for the treatment effect estimated from the BICR to the corresponding 17 
HR for the investigator assessments, is used as the metric to define bias.  The approach is simple to 18 
implement, and ensures a high probability that a substantial true bias will be detected. In the absence of 19 
bias, there is a high probability of accepting the accuracy of local evaluations based on the sample, in 20 
which case an expensive BICR of all patients is avoided.  The properties of the approach are 21 
demonstrated by retrospective application to a completed PIII trial in colorectal cancer.  The same 22 
approach could easily be adapted for other disease settings, and for test statistics other than the hazard 23 
ratio. 24 
Keywords: progression, sample, independent review, oncology 25 
Introduction 26 
Progression Free Survival (PFS) is often accepted as a valid endpoint in oncology both for assessing 27 
activity and for registration of drugs.   PFS, defined as the earliest of disease progression or death, is a 28 
time-to-event endpoint which assesses the relative rate with which the disease worsens.  Standard 29 
criteria, such as RECIST 1.1 [1] are applied to calculate the PFS time for each individual.  The longest 30 
diameters of a set of target lesions are measured repeatedly over time, together with an overall 31 
assessment of other non-target lesions and whether any new lesions appear.  Disease progression 32 
occurs if either the sum of target lesions has increased by 20% from the nadir or there is, in the 33 
investigator’s opinion, clear progression of non-target lesions or a new lesion detected. 34 
Whilst the criteria appear largely objective there remains a degree of judgement and measurement 35 
error [2]. Furthermore, a high rate of disagreement, 50% in some cases [3], has been observed between 36 
readers in the timing of progression; much of this is attributed to different readers selecting different 37 
target lesions.   This level of discordance has led to the widespread use of a blinded, independent, 38 
central review (BICR) to confirm and even replace the investigators’ assessment of progression when 39 
this is the primary endpoint.   Not only is a BICR expensive, up to $4-5M for a Phase III trial, it may also 40 
introduce new problems and can by itself introduce bias:  if the investigator decides there is progression 41 
earlier than the BICR then no more tumour assessments will be available to the BICR and the only option 42 
for the BICR analysis is to censor patients at the time the investigator defines progression.   This 43 
censoring is likely to be informative and thus, if the rate of such censoring differs between arms, then, 44 
whilst the BICR assessments remain informative, bias will be introduced in the estimation of the BICR 45 
hazard ratio (HR) [4]. 46 
We are most interested in whether the disagreement between readers in the time of progression for 47 
individual patients results in a biased estimate of a treatment effect.   A number of reviews [4-6], have 48 
shown a high concordance between the local evaluation (LE) HR estimated by the investigator and HR 49 
estimated by the BICR, particularly in blinded trials, although there is some overlap in the trials 50 
considered in these reviews.  Given the cost and complexity of a BICR, the idea of performing the 51 
independent review amongst a sample of patients has emerged: if the sample satisfactorily rules out the 52 
presence of bias then no more scans are re-read, otherwise the BICR is performed in all patients.  An 53 
Oncology Drugs Advisory Committee (ODAC) meeting was convened in July 2012 [7] to discuss this 54 
concept and all the committee members supported the notion of a sample review. 55 
There are currently two main methods for conducting a sample review, in this paper we present a third.    56 
In [8], the authors define θC to be the log hazard ratio when progression is evaluated by BICR and they 57 
test the null hypothesis H0: θC ≥ γ, where the threshold γ is termed the “clinical irrelevance factor”. The 58 
testing procedure uses estimates of θC based on (i) LE of the full set of patients plus BICR of a sample of 59 
patients or, if it is deemed appropriate, (ii) BICR of the full sample. The estimate of θC in (i) is a 60 
combination of HR estimates from LE and BICR data chosen to have minimum variance, given the 61 
correlation between LE and BICR estimates of HR (which can be estimated by bootstrapping the audited 62 
cases). Since H0 can be tested twice, a multiple testing procedure is used to protect the overall type I 63 
error rate: it is a non-significant result in the first of these tests (when the upper limit of a 1-α/2 64 
confidence interval is greater than γ) that leads to a BICR of the full data set.  65 
 66 
The second method [5] concludes that bias is absent if appropriately defined measures of discordance in 67 
progression times are similar between treatment arms.  The philosophy of this second approach is to 68 
regard the sample review as an audit to assess whether there is evidence of bias in the local evaluation 69 
for that particular trial, rather than to re-test statistical significance.   The discordance measures, late 70 
and early discrepancy rate (LDR and EDR), are compared between treatment arms and were chosen as 71 
they were found to be sensitive to bias [9].   The LDR quantifies the frequency that the LE declares 72 
progression later than the BICR as a proportion of the total number of discrepancies in the timing of 73 
progression.  The EDR quantifies the frequency with which the LE declares progression early relative to 74 
BICR as a proportion of the total number of investigator assessed progressions.  Initially, the authors 75 
proposed accepting the sample if the observed values of LDR and EDR were less than a fixed acceptance 76 
threshold but later proposed modifying the approach [10] to allow the acceptance thresholds to vary by 77 
design in order to guarantee the same high probability that bias would be detected if the LE and BICR 78 
HRs differed by a fixed proportion.   As a result, in order to utilise the Amit method an error model must 79 
first be set-up [9] by the user to define the appropriate sample acceptance thresholds, and this can 80 
make transferring the method between different researchers a challenge.   The performance of these 81 
two existing methods has been compared [11]. 82 
 83 
The model free audit approach presented in this paper is based on an approach to futility analyses 84 
developed to be used in group sequential designs. The approach has features in common with both the 85 
Dodd and Amit methods; it is simple to implement and reliably identifies bias.  In common with the 86 
Dodd method it utilises the HRs directly and in common with the Amit method it aims to detect bias in 87 
terms of differences in treatment effect estimates rather than to re-test statistical significance.  A key 88 
advantage of the approach lies in its simplicity and hence the ease with which it can be applied by 89 
different researchers. 90 
The paper is structured as follows:  firstly the methodology is outlined, followed by a results section 91 
identifying the likely sample sizes required to have appropriate sensitivity and specificity.   The approach 92 
is then retrospectively applied to data from a trial in metastatic colorectal cancer, where the BICR was 93 
performed in all patients in order to confirm the analytical findings.  Finally the paper discusses potential 94 
applications and practical considerations. 95 
 Methods 96 
The primary inference of the model-free audit procedure concerns the point estimate for the hazard 97 
ratio ratio (HRR) in the full data set, which is equal to the point estimate of BICR HR divided by the point 98 
estimate of the LE HR.  In the model-free approach, absence of bias, or more precisely lack of evidence 99 
of meaningful bias, is concluded if there is a low conditional probability that the HRR seen in the random 100 
sample of patients would have been observed if, in fact, the point estimate of the HRR in the full trial 101 
were unacceptably high, 1.25 for example. In the discussion section we explore this choice in more 102 
detail. 103 
If no bias is found the sample is accepted and no further scans are assessed by the BICR, otherwise the 104 
BICR is performed in all patients.  We propose that the estimate of treatment effect should be based on 105 
the local evaluation if either the sample is accepted or if the BICR is performed in all patients and there 106 
is insufficient evidence of bias, but if the BICR in the full trial indicates the presence of bias then 107 
inference about the treatment effect should be based on the BICR.  In practical terms, the sample for 108 
BICR assessment is drawn at completion of the trial.  The patients that form this sample are randomly 109 
selected within each treatment arm, with separate sampling within patients with progression events 110 
and with censored times to event according to the LE. All scans from sampled patients are then assessed 111 
by the BICR.    112 
The proposed process for generating the BICR sample and its evaluation is set out in Figure 1. 113 
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Figure 1 Process for selecting the sample for BICR and evaluating the sample results 137 
 138 
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Statistical model and assumptions: 140 
Under the assumption of proportional hazards, denote the hazard ratio between the control and 141 
experimental treatment by 142 
𝐻𝑅 =
𝐻𝑎𝑧𝑎𝑟𝑑 𝑟𝑎𝑡𝑒 𝑜𝑓 𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡
𝐻𝑎𝑧𝑎𝑟𝑑 𝑟𝑎𝑡𝑒 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑎𝑟𝑚
 , 143 
so a value of 𝐻𝑅 below 1 indicates the new treatment is superior to control. 144 
Denote the estimate of 𝐻𝑅 based on the full data set and BICR evaluations of progression by 145 
𝐻?̂?𝐵𝐼𝐶𝑅,𝐹 146 
and the estimate of 𝐻𝑅 based on the full data set and local evaluations of progression by 147 
𝐻?̂?𝐿𝐸,𝐹 . 148 
We suppose that, as the gold standard, the BICR evaluations provide an unbiased estimate of the true 149 
𝐻𝑅, while the local evaluations may be biased. The estimated Hazard Ratio Ratio based on the full data 150 
set is 151 
𝐻𝑅?̂?𝐹 =  
𝐻?̂?𝐵𝐼𝐶𝑅,𝐹
𝐻?̂?𝐿𝐸,𝐹
  152 
and we write its large sample distribution, expressed on the log scale, as 153 
ln(𝐻𝑅?̂?𝐹) ~ 𝑁( ln(𝐻𝑅𝑅) , 𝐼𝐹
−1 ) . 154 
Here the true Hazard Ratio Ratio, 𝐻𝑅𝑅, is defined through the equation  ln(𝐻𝑅𝑅) =155 
𝐸(ln ( 𝐻?̂?𝐵𝐼𝐶𝑅,𝐹 𝐻?̂?𝐿𝐸,𝐹⁄ ) ) and 𝐼𝐹 denotes the Fisher information for ln(𝐻𝑅𝑅) in the full data set. After 156 
assessment of the sample of the data, we have the estimate of 𝐻𝑅 based on BICR evaluations, 𝐻?̂?𝐵𝐼𝐶𝑅,𝑆, 157 
and the estimate of 𝐻𝑅 based on local evaluations of sampled subjects, 𝐻?̂?𝐿𝐸,𝑆. The estimate of the 158 
Hazard Rate Ratio based on the sample is 159 
𝐻𝑅?̂?𝑆 =  
𝐻?̂?𝐵𝐼𝐶𝑅,𝑆
𝐻?̂?𝐿𝐸,𝑆
 160 
and the large sample distribution of this estimate is given by  161 
ln(𝐻𝑅?̂?𝑆) ~ 𝑁( ln(𝐻𝑅𝑅) , 𝐼𝑆
−1 ) , 162 
where 𝐼𝑆 denotes the information for ln(𝐻𝑅𝑅) in the sample data. We proceed on the assumption that 163 
the estimates ln(𝐻𝑅?̂?𝑆) and ln( 𝐻𝑅?̂?𝐹) have the canonical form of joint distribution described in 164 
Jennison & Turnbull, Ch. 11 [12]. Specifically, the two estimates are bivariate normal with means and 165 
variances as stated above and their covariance is 𝐼𝐹
−1. It follows that the conditional distribution of 166 
ln(𝐻𝑅?̂?𝑆) given 𝐻𝑅?̂?𝐹 = 𝐻𝑅?̃?𝐹  is 167 
ln(𝐻𝑅?̂?𝑆) |  𝐻𝑅?̂?𝐹 = 𝐻𝑅?̃?𝐹    ~  𝑁(ln(𝐻𝑅?̃?𝐹), 𝐼𝑆
−1 − 𝐼𝐹
−1). 168 
Standardised test statistics are defined as 169 
𝑍𝐹 =  ln(𝐻𝑅?̂?𝐹) √𝐼𝐹   and   𝑍𝑆 =  ln(𝐻𝑅?̂?𝑆) √𝐼𝑆  170 
 and the conditional distribution of 𝑍𝑆 given 𝑍𝐹 = ?̃?𝐹 (so ln(𝐻𝑅?̂?𝐹) = ?̃?𝐹/√𝐼𝐹  ) is 171 
𝑍𝑆 |  𝑍𝐹 = ?̃?𝐹   ~   𝑁 (?̃?𝐹
√𝐼𝑆
√𝐼𝐹
 ,
𝐼𝐹−𝐼𝑆
𝐼𝐹
)             (1). 172 
When analysing the sample data, we specify a maximum acceptable value 𝐻𝑅𝑅𝑈 (for example, as 173 
suggested Error! Reference source not found.) for  𝐻𝑅?̂?𝐹 and test the null hypothesis 𝐻0: 𝐻𝑅?̂?𝐹 ≥174 
 𝐻𝑅𝑅𝑈 against the alternative 𝐻1: 𝐻𝑅?̂?𝐹 <  𝐻𝑅𝑅𝑈. Note that these hypotheses concern 𝐻𝑅?̂?𝐹 , the final 175 
estimate of 𝐻𝑅𝑅. The distribution of 𝑍𝑆 given 𝐻𝑅?̂?𝐹 =  𝐻𝑅𝑅𝑈, the case at the boundary of the null 176 
hypothesis, is given by (1) with ?̃?𝐹 =  ln(𝐻𝑅𝑅𝑈 ) √𝐼𝐹 and 𝑍𝑆 will tend to take lower values under 𝐻1. So, 177 
for a level α test, we stop and reject H0 based on the sample of data if 178 
𝑍𝑆  <   ln(𝐻𝑅𝑅𝑈 ) √𝐼𝑆  −  𝛷
−1(1 − 𝛼)√
𝐼𝐹 − 𝐼𝑆
𝐼𝐹
 ,      (2) 179 
where 𝛷 is the standard normal cumulative distribution function. This criterion can be expressed as a 180 
bound on the estimated 𝐻𝑅?̂?𝑆 from the data sample: 181 
ln(𝐻𝑅?̂?𝑆)  <   ln(𝐻𝑅𝑅𝑈) − 𝛷
−1(1 − 𝛼)√
𝐼𝐹 − 𝐼𝑆
𝐼𝑆𝐼𝐹
  182 
or, equivalently, 183 
𝐻𝑅?̂?𝑆   <  𝑒𝑥𝑝 [ ln(𝐻𝑅𝑅𝑈) −  𝛷
−1(1 − 𝛼)√
(𝐼𝐹−𝐼𝑆)
𝐼𝑆𝐼𝐹
    ]  = 𝐴𝑇,   say,     (3) 184 
where 𝐴𝑇 indicates the “acceptance threshold” for the Hazard Ratio Ratio observed in the sample data. 185 
If the above test does not reject 𝐻0, BICR is conducted for the full set of data so 𝐻𝑅?̂?𝐹  is known exactly 186 
and there is then no error in determining whether or not 𝐻0 is true. Thus, the type I error probability α 187 
assigned to the analysis of the sample data is the total type I error probability for testing 𝐻0: 𝐻𝑅?̂?𝐹 ≥188 
 𝐻𝑅𝑅𝑈. 189 
Suppose now that the full data estimate of 𝐻𝑅𝑅 takes the value  𝐻𝑅?̂?𝐹 = 1. We refer to the probability 190 
of stopping to reject 𝐻0 after analysing the sample data in this case as the “specificity” of the method. 191 
Conditionally, given 𝐻𝑅?̂?𝐹 = 1, 𝑍𝑆 ~ 𝑁 (0 ,
𝐼𝐹−𝐼𝑆
𝐼𝐹
) and the probability of satisfying (2), the specificity, is 192 
𝛷 [ ln(𝐻𝑅𝑅𝑈) √
𝐼𝑆𝐼𝐹
(𝐼𝐹−𝐼𝑆)
   −  𝛷−1(1 − 𝛼) ] =  𝛷 [ln(𝐴𝑇)√
𝐼𝑆𝐼𝐹
(𝐼𝐹−𝐼𝑆)
  ].      (4) 193 
Values of 𝐼𝐹 and 𝐼𝑆 194 
For a two-treatment comparison with randomisation ratio 𝑘 ∶ 1 between treatment arms, we use the 195 
result 196 
𝑉𝑎?̂?(ln(𝐻?̂?) )  ≅   
(𝑘 + 1)2
𝑘 𝑛
 197 
from [12]. In the full data with 𝑛𝐿,𝐹 LE events and  𝑛𝐵,𝐹 BICR events, we have, approximately, 198 
𝑉𝑎𝑟(ln(𝐻?̂?𝐵𝐼𝐶𝑅,𝐹) )  =  
(𝑘+1)2
𝑘𝑛𝐵,𝐹
    and    𝑉𝑎𝑟(ln(𝐻?̂?𝐿𝐸,𝐹) )  =  
(𝑘+1)2
𝑘𝑛𝐿,𝐹
 , 199 
so if 𝐶𝑜𝑟𝑟(ln(𝐻?̂?𝐵𝐼𝐶𝑅,𝐹), ln(𝐻?̂?𝐿𝐸,𝐹))  =  𝜌, we obtain 200 
𝑉𝑎𝑟(ln(𝐻𝑅?̂?𝐹)) = 𝑉𝑎𝑟(ln(𝐻?̂?𝐵𝐼𝐶𝑅,𝐹) − ln(𝐻?̂?𝐿𝐸,𝐹))  =   
(𝑘+1)2
𝑘𝑛𝐵,𝐹
 +    
(𝑘+1)2
𝑘𝑛𝐿,𝐹
 −  2 𝜌
(𝑘+1)2
𝑘
 √
1
𝑛𝐵,𝐹𝑛𝐿,𝐹
 . 201 
Defining 𝑟 = 𝑛𝐵,𝐹 𝑛𝐿,𝐹⁄ , we have 202 
𝐼𝐹  =  [𝑉𝑎𝑟(ln(𝐻𝑅?̂?𝐹) )]
−1  =  
𝑘 𝑛𝐿,𝐹
(𝑘+1)2
 
𝑟
( 1+𝑟−2𝜌√𝑟 )
.                   (5) 203 
In the data sample, let 𝑛𝐿,𝑆 denote the number of LE events and 𝑛𝐵,𝑆 the number of BICR events. By a 204 
scaling argument, we expect the ratio 𝑛𝐵,𝑆 𝑛𝐿,𝑆⁄  to be close to 𝑟 and, approximately, 205 
𝐼𝑆  =  [𝑉𝑎𝑟(ln(𝐻𝑅?̂?𝑆) )]
−1  =  
𝑘 𝑛𝐿,𝑆
(𝑘+1)2
 
𝑟
( 1+𝑟−2𝜌√𝑟 )
.                       (6) 206 
One practical consideration is how to estimate the correlation 𝜌  between ln(𝐻?̂?𝐵𝐼𝐶𝑅) and ln(𝐻?̂?𝐿𝐸).    207 
We have followed [8], and estimated the correlation using a bootstrap approach.  In the sample there 208 
are nsample patients of whom 𝑛𝐿,𝑆 have events according to the LE.  In the bootstrap calculations, the 209 
nsample subjects are sampled with replacement, stratified by treatment arm and whether the patients had 210 
an event, to create a sample of size nsample.  Using both the LE and BICR determined PFS times, 211 
ln(𝐻?̂?𝐵𝐼𝐶𝑅) and ln(𝐻?̂?𝐿𝐸) are computed in the bootstrap sample.  This is repeated b times and the 212 
sample correlation coefficient of ln(𝐻?̂?𝐵𝐼𝐶𝑅) and ln(𝐻?̂?𝐿𝐸) provides the estimate of 𝜌.  Results 213 
presented in the supplementary appendix support the assumption that this correlation is independent 214 
of the size of the sample and, in particular, that  Corr(ln(HR̂BICR,S) , ln (HR̂LE,S)) = Corr(ln(HR̂BICR,F),215 
ln(HR̂LE,F)) . 216 
 Results 217 
We have investigated the methods described above in an example with a total sample size of Nstudy= 500 218 
patients and a selection of values for the audit sample size nsample. We have assumed 60% of patients 219 
have an event according to local evaluation and 55% according to BICR. The lower event rate for BICR 220 
reflects the fact that any BICR progressions occurring after local evaluation progression are unlikely to 221 
be captured. The acceptance threshold, AT, is calculated from (3) using 𝛼 = 0.1 and values of 𝐼𝐹 from (5) 222 
and  𝐼𝑆 from (6) with k=1 and r=0.55/0.6=0.92.  The specificity, the probability of accepting local 223 
evaluations based on the sample if 𝐻𝑅?̂?𝐹 = 1, is found from (4). 224 
Results for different scenarios are shown in Figures 2 to 5. By construction, with 𝛼 = 0.1 the sensitivity, 225 
defined as the probability of accepting  𝐻0 when 𝐻𝑅?̂?𝐹 =  𝐻𝑅𝑅𝑈, is 90% in all cases. For a given total 226 
sample size Nstudy, the acceptance threshold and the specificity change with the correlation 𝜌 between 227 
local evaluation and BICR (Figure 2), the size nsample of the audit sample (Figure 3), and the value 𝐻𝑅𝑅𝑈 228 
of  𝐻𝑅?̂?𝐹 used to define 𝐻0 (Figure 4). We see that the acceptance threshold and specificity increase 229 
with each of 𝜌, nsample and  𝐻𝑅𝑅𝑈. Figure 5 demonstrates how the acceptance threshold and specificity 230 
vary with total sample size Nstudy when nsample is fixed at a value of 200.231 
 232 
Figure 2 Acceptance threshold, AT, and specificity by correlation, ρ  (Nstudy=500, nsample = 200, proportion of patients with 233 
events = 0.6 for LE and 0.55 for BICR, testing 𝑯𝟎: 𝑯𝑹?̂?𝑭 ≥ 𝑯𝑹𝑹𝑼 = 𝟏. 𝟐𝟓) 234 
 235 
 236 
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 237 
Figure 3 Acceptance threshold, AT, and specificity by sampling proportion, nsample   (ρ = 0.7, Nstudy=500, proportion of patients 238 
with events = 0.6 for LE and 0.55 for BICR, testing 𝑯𝟎: 𝑯𝑹?̂?𝑭 ≥ 𝑯𝑹𝑹𝑼 = 𝟏. 𝟐𝟓) 239 
 240 
Figure 4 Acceptance threshold, AT, and specificity by the value of 𝑯𝑹𝑹𝑼 used to specify H0  (ρ = 0.7, Nstudy=500, nsample=200, 241 
proportion of patients with events = 0.6 for LE and 0.55 for BICR) 242 
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Figure 5 Acceptance threshold, AT, and specificity by full study population size Nstudy  (ρ = 0.7, nsample=200, proportion of 244 
patients with events = 0.6 for LE and 0.55 for BICR, testing 𝑯𝟎: 𝑯𝑹?̂?𝑭 ≥= 𝑯𝑹𝑹𝑼 = 𝟏. 𝟐𝟓) 245 
With a sample of 200 patients from a total of Nstudy=500, testing 𝐻0: 𝐻𝑅?̂?𝐹 ≥ 𝐻𝑅𝑅𝑈 = 1.25, Figure 2 246 
shows that under an assumed correlation of ρ = 0.7, the acceptable sample threshold is AT=1.08 and the 247 
specificity is 0.76.  As the correlation increases the specificity increases sharply, while the impact on the 248 
threshold is smaller, with AT rising from 0.97 for ρ = 0.1 to 1.15 for ρ = 0.9. Figure 3 shows that 249 
specificity increases with the size of the sample, nsample, for example with nsample=300, we have AT=1.14 250 
and the specificity is 0.96.  However, specificity decreases steeply as the sample size is reduced below 251 
200, for example, specificity is only 0.47 for nsample=100. Figure 4 shows that the acceptance threshold 252 
and specificity increase with 𝐻𝑅𝑅𝑈, with specificity close to 1 by the time 𝐻𝑅𝑅𝑈 reaches 1.4. Analyses of 253 
previous trials at AstraZeneca have indicated a fairly stable estimate of correlation between local 254 
evaluation and BICR around 0.7 .  In planning to apply the methodology described in this paper, the 255 
sample size can be calculated for an estimated value of the correlation ρ. While it is possible, in 256 
principle, to adjust the sample size in the light of observed data and an updated estimate of ρ, 257 
requesting additional central reviews could cause delays, making this approach impractical. A simpler 258 
option is to aim to err in the direction of under-estimating ρ then, as seen in Figure 2, if the true value of 259 
ρ is higher than this estimate, specificity will be higher than the design value. 260 
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Operating Characteristics by Simulated Retrospective Application to 261 
a Phase III Trial in First Line Metastatic Colorectal Cancer 262 
In this section, we demonstrate that when the proposed method is applied in practice, the observed 263 
sensitivity and specificity align closely with the theory presented in the previous sections. This is 264 
achieved by repeated simulation of sample BICR results for a large clinical trial dataset. 265 
 Study Background 266 
The proposed sample audit BICR approach was simulated by repeatedly applying it to data from a large 267 
randomised double blind study in first-line metastatic colorectal cancer (mCRC) with 1:1 randomisation 268 
in 1422 patients [14].  In this study, the duration of progression free survival for all patients was derived 269 
according to a local investigator evaluation (LE) and according to a supportive blinded independent 270 
central review (BICR). The primary results from analyses of the LE and BICR data are summarised in 271 
Table 1 and Table 2  below. 272 
Table 1 Local Evaluation of PFS in a study of mCRC 273 
Randomised 
Treatment Arm 
Number of Patients 
(Number of 
Progression Events) 
Hazard Ratio 95% Confidence 
Interval For Hazard 
Ratio 
Active Treatment 709 (471) 1.103 (0.97,1.25) 
Control Treatment 713 (453)   
 274 
Table 2 BICR Evaluation of PFS in a study of mCRC 275 
Randomised 
Treatment Arm 
Number of Patients 
(Number of 
Progression Events) 
Hazard Ratio 95% Confidence 
Interval for Hazard 
Ratio 
Active Treatment 709 (377) 1.041 (0.90, 1.20) 
Control Treatment 713  (377)   
 276 
 Demonstrating Sensitivity for a given Null Distribution 277 
In the full study data reported above, the value of 𝐻𝑅?̂?𝐹 is 𝐻?̂?𝐵𝐼𝐶𝑅,𝐹/𝐻?̂?𝐿,𝐹 = 0.944.  With both 278 
𝐻?̂?𝐵𝐼𝐶𝑅,𝐹  and 𝐻?̂?𝐿,𝐹  above 1, there is no evidence of a beneficial treatment effect. Since 𝐻𝑅?̂?𝐹 < 1, 279 
there is no indication of bias in the LE in favour of the active therapy. In order to use this example to 280 
demonstrate the theoretical properties introduced in the Methods section, we suppose that 𝐻𝑅𝑅𝑈 is set 281 
to be 0.944 ‒ even though a value greater than 1 would usually be specified. We, therefore, wish to test 282 
the null hypothesis 283 
𝐻0: 𝐻𝑅?̂?𝐹 ≥  0.944. 284 
This 𝐻0 is true for the given data set, so 𝐻0 should be accepted and a full sample audit initiated based on 285 
the BICR sample with probability 1 − 𝛼 = 0.9.  Our objective is to demonstrate that the conclusion that 286 
a full sample audit should be conducted arises with this probability in simulations of the proposed 287 
method. 288 
In each of 10000 simulations, we created a BICR sample dataset in the manner described in Figure 1. We 289 
first used a 30% sampling rate, so each sample contained 30% of patients with events and 30% of 290 
patients with censored events within each treatment arm. 291 
 292 
For 1000 of the simulated datasets, we created 100 bootstrap samples and used these to estimate the 293 
correlation 𝜌 between ln(𝐻?̂?𝐿𝐸) and ln(𝐻?̂?𝐵𝐼𝐶𝑅).  The median value obtained in the 1000 datasets was  294 
𝜌 = 0.66 and we have taken this as our overall estimate of 𝜌. Table 1 shows a total of 𝑛𝐿,𝐹 = 924 LE 295 
events and Table 2 a total of 𝑛𝐵,𝐹 = 754 BICR events, so 296 
 297 
𝑟 =  
𝑛𝐵,𝐹
𝑛𝐿,𝐹
=
754
924
= 0.816. 298 
 299 
We combined this value of  𝑟 with 𝑘 = 1 and 𝜌 = 0.66 to obtain 300 
 301 
𝐼𝐹  =  [𝑉𝑎𝑟(ln(𝐻𝑅?̂?𝐹) )]
−1  =  
𝑘 𝑛𝐿,𝐹
(𝑘+1)2
 
𝑟
( 1+𝑟−2𝜌√𝑟 )
= 302.271  302 
 303 
and  𝐼𝑆 = 0.3 ×  𝐼𝐹 = 90.681. 304 
 305 
We then carried out the following steps for each of the 10000 simulated BICR sample datasets. 306 
   307 
1) Calculate 𝐻?̂?𝐿,𝑆,  𝐻?̂?𝐵𝐼𝐶𝑅,𝑆   and, hence,  𝐻𝑅?̂?𝑆  for the BICR sample. 308 
 309 
2) Calculate 𝑍𝑆 = ln( 𝐻𝑅?̂?𝑆) √𝐼𝑠 and, following (2), reject  𝐻0: 𝐻𝑅?̂?𝐹 ≥  0.944 if 310 
 311 
𝑍𝑆  <   ln(0.944 ) √𝐼𝑆  − 𝛷
−1(0.9)√
𝐼𝐹 − 𝐼𝑆
𝐼𝐹
 =  −1.624 = 𝐴𝑐𝑐𝑒𝑝𝑡𝑎𝑛𝑐𝑒 𝑇ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 312 
Out of 10000 simulated BICR samples, 8985 (89.9%) led to acceptance of 𝐻0, in close agreement with 313 
the theoretical sensitivity of 90%. The above exercise was repeated using sampling rates of 20%, 40% 314 
and 50%, with 10000 replicates in each case. Again, correlation was assumed to be 0.66 so 𝐼𝐹 remained 315 
the same but 𝐼𝑆 varied with the value of nsample. Table 3Table 3 shows the acceptance threshold for 316 
𝐻𝑅?̂?𝑆,  i.e., AT from equation (3), and the percentage of cases out of 10000 simulations in which 𝐻0 was 317 
accepted. All these estimates of sensitivity are close to 90%. 318 
Table 3 Acceptance Thresholds for 𝑯𝑹?̂?𝑺 and estimated sensitivity for tests of 𝑯𝒐: 𝑯𝑹?̂?𝑭 ≥ 𝟎. 𝟗𝟒𝟒 319 
% Sampling (Number 
of patients) 
Acceptance Threshold, 
AT, for sensitivity  0.9 
under 𝐻0 
Estimated sensitivity 
from 10000 
simulations 
20% (286) 0.814 89.8% 
30% (428) 0.843 89.8% 
40% (570) 0.862 90.2% 
50% (712) 0.877 89.6% 
 320 
The above results concern a single point in the distribution of 𝑍𝑆 . We can go further and compare the 321 
full distribution of the simulated values of 𝑍𝑆 against the theoretical density of 𝑍𝑆 given  𝐻𝑅?̂?𝐹 = 0.944  322 
or, equivalently, 𝑍𝐹 =  ln(𝐻𝑅?̂?𝐹) √𝐼𝐹 = ln(0.944) × √302.271 =  −1.002.  This conditional 323 
distribution of 𝑍𝑆 is given by (1) with  ?̃?𝐹 =  −1.002,  𝐼𝐹 = 302.271 and, for 30% sampling, 𝐼𝑆 = 0.3 ×324 
 𝐼𝐹 = 90.681.  Figure 6 shows a smoothed kernel density estimate based on the simulated values of 𝑍𝑆 325 
for the case of 30% sampling plotted with the conditional density of 𝑍𝑆 | 𝑍𝐹 = −1.002  given by 326 
equation (1). The critical value 𝑍𝑆 =  −1.624, below which  𝐻0 is rejected, is indicated in the figure. 327 
Figure 6 also compares results in terms of  𝐻𝑅?̂?𝑆, showing the smoothed kernel density estimate based 328 
on simulated values of  𝐻𝑅?̂?𝑆 and the theoretical conditional density of  𝐻𝑅?̂?𝑆  given 𝐻𝑅?̂?𝐹 = 0.944. In 329 
this case the critical value for 𝐻𝑅?̂?𝑆, below which  𝐻0 is rejected, is  exp (
−1.624
√90.681
 ) = 0.843,  and this is 330 
also the value 𝐴𝑇 obtained from (3). The results in Figure 6 demonstrate excellent agreement between 331 
the distribution of the simulated data and the theoretical null distribution. 332 
  333 
Figure 6 Observed density of 𝒁𝑺 and 𝑯𝑹?̂?𝑺  (purple) versus density given  𝑯𝑹?̂?𝑭 = 𝟎. 𝟗𝟒𝟒  (red) 334 
Demonstrating Specificity for a given Null Distribution 335 
We now use the same example to confirm that the theoretically derived value for specificity is observed 336 
in practice. To this end, suppose it is desired to test 𝐻0: 𝐻𝑅?̂?𝐹 ≥  𝐻𝑅𝑅𝑈 = 1.25 with 𝛼 = 0.1. For the 337 
data set we are considering, 𝐻𝑅?̂?𝐹 = 0.944, and 𝐼𝐹 = 302.271. With 𝑘% sampling, 𝐼𝑆 = (
𝑘
100
) × 𝐼𝐹  338 
and equation (4) gives the specificity under  𝐻𝑅?̂?𝐹 = 0.944  as 339 
𝛷 [ (ln(1.25) −  ln (0.944)) √
𝐼𝑆𝐼𝐹
(𝐼𝐹−𝐼𝑆)
   −  𝛷−1(0.9) ] =  𝛷 [ ln(1.324) √
𝑘 × 302.271
(100−𝑘)
   −  𝛷−1(0.9) ]  (7)   340 
Table 4 compares the estimated specificity, based on 10000 simulated BICR samples, with the values 341 
given by (7) for 20%, 30%, 40% and 50% sampling. We see that in each case the estimated specificity is a 342 
little higher than the theoretical value. While the differences are greater than might be explained by the 343 
sampling error in 10000 replications, they are still small and do not give any serious cause for concern. 344 
Table 4 Acceptance Threshold for testing H0: HRR ≥ 1.25, Estimated Specificity based on 10000 Simulations and Theoretical 345 
Specificity from Equation (7) 346 
% Sampling 
(Number of patients) 
Acceptance Threshold 
AT for testing 
 Ho: 𝐻𝑅?̂?𝐹 ≥  1.25 
Estimated 
specificity from 
simulations 
Theoretical 
Specificity 
20% (286) 1.079 88.9% 87.7% 
30% (428) 1.117 97.8% 97.2% 
40% (570) 1.142 99.76% 99.66% 
50% (712) 1.161 100% 99.98% 
“Real life” Properties of the Method  347 
In the preceding calculations and simulations regarding sensitivity and specificity, we have used the full 348 
study information to define 𝑟 = 𝑛𝐵,𝐹/𝑛𝐿,𝐹, to compute 𝐼𝐹, and to find a bootstrap estimate of 𝜌. In 349 
practice, this complete information would not be known at the time of carrying out a sample BICR. 350 
Instead, we would use the information in the sample, directly calculating 𝐼𝑠 from the estimated 351 
variances of the log hazard ratios for the sample BICR and sample LE data returned by standard software 352 
packages and a separate bootstrap estimate of 𝜌 from each sample. 𝐼𝐹 could then be calculated as   353 
𝛾−1𝐼𝑠, where 𝛾 is the sampling fraction used.  354 
In order to assess the proposed procedure as it would be used in practice, we analysed the same sets of 355 
simulated samples from the previous section in this way. The percentages of simulations in which 𝐻0: 356 
𝐻𝑅?̂?𝐹 ≥  0.944  was not rejected are given in Table 5. 357 
Table 5 Estimated sensitivity for tests of 𝑯𝒐: 𝑯𝑹?̂?𝑭 ≥ 𝟎. 𝟗𝟒𝟒 when 𝑰𝑺, 𝑰𝑭 and 𝝆 are estimated from information in the 358 
sample data only 359 
% Sampling 
(Number of patients) 
Estimated Sensitivity 
from 10000 simulations 
20% (286) 92.23% 
30% (428) 92.15% 
40% (570) 92.23% 
50% (712) 91.72% 
 360 
The observed sensitivities are close to the intended value of 90% and perhaps slightly conservative, i.e., 361 
with an error rate under 𝐻0 below  𝛼 = 0.1. 362 
We have repeated the calculations of sensitivity and specificity in simulated sample data sets from a 363 
smaller study of 196 gliobastoma patients who were randomised in a ratio of 2 to 1 between 364 
experimental and control treatments. We found similarly agreement between theoretical and empirical 365 
properties of the proposed procedure, including the “real-life” case where values for 𝑟, 𝐼𝐹 and 𝜌 based 366 
on the sample data sets themselves. (See Appendices.) 367 
 Discussion: Practical Considerations and Potential Applications 368 
Methods 369 
We have presented a method whereby a sample of centrally reviewed cases can be used to decide if a 370 
full review of local assessments of progression free survival is needed. This method is simple to apply 371 
and effective in reducing the volume of BICR when the audit of a sample of patients supports use of the 372 
hazard ratio from local evaluation in determining the study conclusion. The method’s theoretical 373 
statistical properties have been confirmed in examples of historical data from Phase III trials of 374 
metastatic colorectal cancer and gliobastoma.  375 
In the proposed method, we define a null hypothesis under which the level of bias in local evaluations is 376 
unacceptable. If the audit sample leads to rejection of this null hypothesis, we conclude that local 377 
evaluations are sufficiently close to independent reviews (or biased against the experimental treatment) 378 
and a full BICR is unnecessary. The approach is in keeping with the idea that a full study BICR is 379 
appropriate unless there is evidence to demonstrate this is not necessary. 380 
If the audit sample triggers a full study BICR and the hazard ratio ratio observed in the full-study data 381 
indicates a difference between the LE and BICR estimates of hazard ratio, then both these estimates 382 
may be subject to bias. The LE sample may indicate progression that BICR does not confirm, while 383 
limited availability of post-progression scans causes informative censoring for the BICR estimate.  384 
Methods have been proposed for such a BICR situation, for example to include an event at the visit 385 
subsequent to the LE progression [16].  Another possibility in this situation could be a multiple 386 
imputation approach [17]. 387 
We have presented a situation with a single value of maximum acceptable HRR (1.25) to illustrate the 388 
proposed method.  In practical application, we propose that a graded approach be taken, such that the 389 
limit varies depending on the observed LE HR.  It would seem logical to have greater tolerance for 390 
possible bias (higher HRR, >1) in the presence of a strong treatment effect according to the LE HR, and 391 
smaller tolerance (lower HRR, closer to 1) in the case of a weaker LE treatment effect. A possible graded 392 
approach to satisfy this requirement would be to set the HRR threshold such that it preserves the 393 
majority of the observed LE HR. Table 6 for example, illustrates the HRR which would result from 394 
preserving 2/3rds of the observed full study LE HR for a range of LE hazard ratios.   Using this approach it 395 
is suggested the sample is designed to have sufficient specificity against the HRR that corresponds to the 396 
minimally clinically important LE HR. 397 
Table 6 Graded Approach to Choice of HRR Threshold 398 
Full Study Local Evaluation 
Hazard Ratio 
HRR Threshold to preserve 2/3rd 
of LE HR 
0.3 1.78 
0.5 1.33 
0.7 1.14 
0.9 1.04 
 399 
We have proposed using an alpha of 10% instead of the typical 2.5%.   Given the prior data consistently 400 
demonstrating the concordance in treatment effects estimated by the BICR and LE we feel this is 401 
appropriate in most situations.    402 
Application of the proposed method requires an initial estimate of the correlation between LE and BICR 403 
hazard ratio estimates. In principle, the correlation observed in the first part of an audit sample could be 404 
used to re-calculate the necessary sample size. However, for simplicity of application, it may well be 405 
preferable to adopt a conservative approach and assume a low value for the correlation, since this will 406 
lead to a specificity above the target value as long as the estimated correlation is below the true value.  407 
For studies with long durations, or known operational changes during conduct, a stratified approach 408 
could be followed (e.g., early/late, before/after) where correlations, and HRR estimates, are allowed to 409 
vary between levels of the stratification factor.  The BICR sample would select proportionately from 410 
each level, so that the overall HRR estimate is representative of the whole study.  Alternatively, if there 411 
was concern about the potential for bias in certain subgroups of patients, such as those with non-412 
measurable disease, these patients could be enriched in the sample.   In this case, the HRR in each 413 
subgroup would need re-weighting to provide an estimate of the HRR in the overall population. 414 
Practical Implementation 415 
The practical considerations for performing a BICR can be challenging.  To benefit most from the 416 
proposed approach, the study should be sufficiently large that an audit sample size can be chosen which 417 
is big enough to determine whether a full BICR is necessary, yet small enough that carrying out BICR only 418 
for this audit sample represents a worthwhile saving.  Our experience indicates that $1-$1.25m could be 419 
saved if 50% of a trial were sampled, with the costs for the process being equally split between 420 
collecting and reading the scans.   Plans should be in place to collect and store scans from all patients, 421 
with which there is an associated cost. 422 
There are two potential options for implementation. The sample BICR may be initiated prior to database 423 
lock to allow a rapid decision on whether full study review is required, so that such a review can be 424 
conducted without a major impact on reporting timelines.  However, the review process cannot be 425 
started too early since it must not have any impact on the study conduct.  The maximum acceptable HRR 426 
(graded by observed HR(LE)), the sample selection process, and a mechanism for collecting the 427 
appropriate scans promptly should all be prepared at the start of the trial.  One possibility is that an 428 
Independent Data Monitoring Committee, or other independent party, could be supplied, close to 429 
database lock, with the random scheme and PFS data for the LE and BICR in the sample.   They could 430 
then indicate to the sponsor whether the sample had been accepted without revealing either treatment 431 
effect. Alternatively, the decision to initiate the sample BICR could be taken after database lock and the 432 
primary LE analysis results are available to the sponsor. Clearly, if there is no significant treatment effect 433 
according to the LE, the sample BICR would not be required. 434 
If a sample were pre-specified at the trial design stage, a BICR could feasibly be conducted in real time.  435 
Real-time BICR results can be used for improving data quality, and ensuring independent verification 436 
prior to treatment crossover on progression if permitted, during a trial. However, our method identifies 437 
the need for a full BICR based on the observed treatment effect, and not, for example, on observed 438 
quality of data collected.  Assessing sample quality based on emerging treatment effect data is beyond 439 
the scope of this paper. 440 
 441 
Summary 442 
The possibility of requiring expert review of outcomes arises across a range of therapy area indications. 443 
Cardiovascular outcome trials often have evidence of stroke or myocardial infarction centrally reviewed 444 
by an independent cardiologist.  X-rays used to assess scale of bone deterioration in rheumatoid arthritis 445 
patients are also frequently independently reviewed. The proposed methodology has the potential for 446 
more general use. Indeed, its application is likely to be more straightforward when the primary outcome 447 
is measured at a single time point and issues of repeated assessment and possible informative censoring 448 
issue do not arise.  449 
In summary we propose a sampling method that is simple to implement and reliable that would enable 450 
conclusions about bias to be assessed at reduced cost.   451 
 452 
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Appendices 515 
 516 
Consistency in Bootstrap Correlation Estimate with Sample Size 517 
For each of 10000 samples generated for a given sample size (20% - 50% of the whole study [14]), 1000 518 
bootstrap samples were generated in order to estimate the correlation between ln(HRLE) and ln(HRBICR).  519 
The distribution of these correlation estimates is summarised in Table 7. This suggests that the statistical 520 
properties of the correlation estimates do not vary much with the % sampling of the whole study. 521 
Table 7 Summary of Bootstrap Correlation Estimates by size of BICR sample 522 
Sample 
BICR as % 
of total 
study 
 Summary of Correlation between HRLE and HRBICR 
Min 1st 
Quartile 
Median Mean 3rd 
Quartile 
Max 
20% 0.356 0.551 0.586 0.584 0.619 0.743 
30% 0.409 0.559 0.588 0.587 0.617 0.722 
40% 0.429 0.564 0.590 0.589 0.613 0.709 
50% 0.473 0.569 0.591 0.590 0.613 0.704 
 523 
Sensitivity of the method in a trial in Gliobastoma [17] 524 
 525 
Table 8 Local Evaluation of PFS in a study of glioblastoma 526 
Randomised 
Treatment Arm 
Number of Patients 
(Number of 
Progression Events) 
Hazard Ratio 95% Confidence 
Interval For Hazard 
Ratio 
Active Treatment 131 (107) 0.837 (0.59,1.18) 
Control Treatment 65 (47)   
 527 
Table 9 BICR Evaluation of PFS in a study of  glioblastoma 528 
Randomised 
Treatment Arm 
Number of Patients 
(Number of 
Progression Events) 
Hazard Ratio 95% Confidence 
Interval for Hazard 
Ratio 
Active Treatment 131 (109) 1.015 (0.71, 1.48) 
Control Treatment 65  (44)   
 529 
Study HRR = 1.212 530 
Theoretical sensitivity 531 
10000 simulations using 50% sampling were run (to ensure a reasonable number of progression events 532 
within BICR sample time to event analysis). NB/NLE = 153/154 was assumed as fixed for nB/nLE and 𝜌 was 533 
set to 0.67 (the mean and median correlation observed using the bootstrap approach in 1000 earlier 534 
BICR simulations). Figure 7 shows the close concordance between the distribution of the simulated 535 
sample BICRs and the expected distribution. Approximate 90% sensitivity is demonstrated in Table 9.  536 
  537 
 538 
Figure 7 Observed density of 𝒁𝑺 and 𝑯𝑹?̂?𝑺  (purple)  versus density given  𝑯𝑹?̂?𝑭 = 𝟏. 𝟐𝟏𝟐  (red) for the gliobastoma trial  539 
(50% sampling of 196 patients) 540 
 541 
Table 10 Acceptance Thresholds for 𝑯𝑹?̂?𝑺 and estimated sensitivity for tests of 𝑯𝒐: 𝑯𝑹?̂?𝑭 ≥ 𝟏. 𝟐𝟏𝟐 542 
 543 
% Sampling (Number 
of patients) 
Acceptance Threshold, 
AT, for sensitivity  0.9 
under 𝐻0 
Estimated sensitivity 
from 10000 
simulations 
50% (99) 1.015 88.8% 
  544 
